Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
anticonvulsant |
| gptkbp:approvedBy |
gptkb:FDA
1996 |
| gptkbp:ATCCode |
N03AX11
|
| gptkbp:bioavailability |
80%
|
| gptkbp:brand |
gptkb:Qudexy_XR
gptkb:Topamax gptkb:Trokendi_XR |
| gptkbp:CASNumber |
97240-79-4
|
| gptkbp:chemicalFormula |
C12H21NO8S
|
| gptkbp:contraindication |
pregnancy (risk of birth defects)
|
| gptkbp:developedBy |
gptkb:McNeil_Pharmaceutical
|
| gptkbp:discoveredBy |
gptkb:Bruce_Maryanoff
|
| gptkbp:drugClass |
sulfamate-substituted monosaccharide
|
| gptkbp:eliminationHalfLife |
19-23 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:genericAvailable |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
topiramate
|
| gptkbp:KEGGID |
D02366
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antagonizes AMPA/kainate glutamate receptors
blocks voltage-dependent sodium channels enhances GABA activity inhibits carbonic anhydrase |
| gptkbp:MedlinePlusID |
a697012
|
| gptkbp:metabolism |
minimal hepatic
|
| gptkbp:molecularWeight |
339.36 g/mol
|
| gptkbp:patentExpired |
yes
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
15-41%
|
| gptkbp:PubChem_CID |
5284627
9596 CHEMBL1229 DB00273 |
| gptkbp:riskFactor |
metabolic acidosis
teratogenicity kidney stones cognitive side effects |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
weight loss cognitive impairment glaucoma drowsiness metabolic acidosis kidney stones paresthesia |
| gptkbp:UNII |
0W5EE5N20X
|
| gptkbp:usedFor |
epilepsy
migraine prevention alcohol dependence (off-label) bipolar disorder (off-label) weight loss (off-label) |
| gptkbp:bfsParent |
gptkb:4-aminobutanoic_acid
|
| gptkbp:bfsLayer |
6
|